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Summary
The objective of the BREATHE study was to estimate the regional prevalence of chronic
obstructive pulmonary disease (COPD) symptoms within the general population in the
Middle East/North Africa (MENA) region and to document risk factors, disease characteristics
and management using a standardised methodology.
This was an observational population-based survey performed in ten countries in the Middle
East and North Africa (Algeria, Egypt, Jordan, Lebanon, Morocco, Saudi Arabia, Syria,
Tunisia, Turkey and United Arab Emirates), together with Pakistan. A general population
sample of 10,000 subjects 40 years of age in each country or zone was generated from
random telephone numbers. Structured interviews were proposed by telephone. A screening
questionnaire was administered to each subject collecting information on respiratory
symptoms and smoking habits. Subjects with chronic bronchitis or breathlessness and smoking
10 pack·years fulﬁlled the epidemiological deﬁnition of COPD (“COPD” population). This
population then completed a full disease questionnaire, the COPD Assessment Test (CAT) and
a cost-of-disease questionnaire. A randomly selected sample was also assessed by spirometry.
In all, 457,258 telephone numbers were generated and contact was established with
210,121 subjects, of whom 65,154 were eligible and 62,086 accepted to participate. The
overall response rate was 74.2%. 2,187 (3.5%) subjects fulﬁlled the criteria for the “COPD”
population. Evaluable spirometry data were obtained from 1,847 (14.2%) subjects to whom
it was proposed.
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The BREATHE study has collected a large amount of information on COPD variables from a
representative sample of the general population of countries in the MENA region, which can
be compared with other regional COPD initiatives.
© 2012 Elsevier Ltd. All rights reserved.
Introduction
Chronic Obstructive Pulmonary Disease (COPD) is deﬁned by
the Global initiative for chronic Obstructive Lung Disease
(GOLD) as “a common preventable and treatable disease
characterised by persistent airﬂow limitation that is
usually progressive and associated with an enhanced chronic
inﬂammatory response in the airways and the lung to
noxious particles or gases. Exacerbations and comorbidities
contribute to the overall severity in individual patients”.1
COPD is a leading cause of morbidity and mortality
worldwide. In 2001, the Global Burden of Disease project
of the World Health Organisation (WHO) identiﬁed COPD
as the sixth leading cause of mortality in countries of
middle- or low-income, accounting for 4.9% of total deaths.2
A national study performed between 1980 and 2000 in
the USA, identiﬁed COPD as the fourth leading cause of
chronic morbidity and mortality.3 In comparison to many
other chronic diseases, death rates from COPD continue to
rise steadily.4,5 The WHO estimates that by 2020 COPD will
become the third leading cause of death worldwide.1 COPD
is also an important cause of disability and extrapulmonary
complications such as depression, diabetes, cardiovascular
disease and osteoporosis.6,7 Although around 90% of deaths
due to COPD occur in low- or middle-income countries, very
few data on the prevalence of this illness are available
in these countries.8 In contrast, the prevalence of COPD
in high-income countries has been well documented. For
example, prevalence rates of 18% and 9% have been reported
for COPD stages I and II in Iceland,9 26.1% and 10.7% in
Austria,10 and 13.2% for stage I in Germany11 using the BOLD
(Burden of Lung Disease) methodology, an initiative set up to
collect country-speciﬁc data on the prevalence, risk factors
and social and economic burden of COPD using structured
interviews based on questionnaires and spirometry.12
Although COPD is not a curable disease, elimination or
reduction of risk factors can prevent the development or
slow down the progression of the disease. The main risk
factors for the development of COPD are cigarette smoking,
increasing age, exposure to air pollutants resulting from
the burning of wood or other biomass fuels, tuberculosis
and occupational exposures.13,14 The increase in prevalence
of COPD is closely linked to the increase in prevalence
of smoking worldwide, particularly among women and
adolescents.15,16
The main obstacle to the implementation of effective
public health strategies aimed at managing and preventing
COPD is the lack of data relating to COPD prevalence
and burden in low- and middle-income countries. In these
countries, accurate prevalence assessment of COPD is
very important for many reasons, including the ability to
document the impact of COPD on disability, on quality
of life, cost of the disease, but also to help in the
management of the disease and public health planning
through governments and health planners.
In the Middle East and North Africa (MENA) region COPD is
underdiagnosed and detected at a late stage.17 Many people
in this region still consider smoking as a socialising factor and
it is part of their daily lives. In this region, tobacco smoking,
waterpipes (narghile, hookah), use of hashish, and the lack
of laws and regulations that ban smoking and water pipes in
coffee houses and other public places are major contributors
to air pollution and second-hand smoke.18,19 Waterpipe
smoking is prevalent among women because there is less of
a cultural stigma attached to it than to cigarette smoking.20
In the 2011 WHO report on the global tobacco epidemic,
smoking rates in the MENA region ranged from 15.1% in
Morocco to 38.5% in Lebanon.7 COPD is therefore a growing
problem in MENA due to the lack of awareness of the risks
associated with smoking.
In the MENA region, as elsewhere in the developing
world, available data on the epidemiology of COPD
are limited. Although several local studies have been
performed,21 24 these have not always been population-
based or nationwide, and have varied with respect to the
age group and the methods used. For these reasons, the
data obtained are difﬁcult to compare between studies
and with those obtained from other regional initiatives into
the epidemiology of COPD such as BOLD,12 PLATINO25 and
Confronting COPD.26
For these reasons, we have carried out a large population-
based epidemiological study of COPD in the MENA region
(BREATHE) using a consistent standardised methodology
which is inspired by that used in the Confronting COPD
surveys in North America and Europe.26 The objective of the
study was to collect standardised population-based data on
COPD throughout the region that can be compared to data
from other regions of the world. The BREATHE project has
collected information on prevalence, burden, management
and resource consumption of COPD in eleven countries in the
MENA region. This article describes the methodology used in
the study.
Objectives
The primary objective of the BREATHE study was to
estimate the prevalence of COPD symptoms within the
general population of participating countries in the MENA
region. Secondary objectives were to document risk factors,
to characterise the COPD population, to describe the
management and the burden of the disease and to estimate
related resource consumption.
Study design
The BREATHE study was a cross-sectional, observational,
population-based survey of COPD. The project was con-
ceived as a series of six independent parallel studies
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Algeria
N=3,714
Morocco
N=3,992
Tunisia
N=1,956
Lebanon
N=3,467
Egypt
N=9,868
Saudi Arabia
N=9,779
UAE
N=3,516
Pakistan
N=3,655
Turkey
N=15,086
Jordan
N=3,621
Syria
N=3,432
Figure 1. Participating countries and numbers of subjects enrolled in the BREATHE study.
performed using an identical protocol in four individual
countries (Egypt, Pakistan, Saudi Arabia and Turkey) and
in two zones including more than one country, namely
North Africa zone (including Algeria, Morocco, and Tunisia)
and Middle East zone (including Jordan, Lebanon, Syria,
and UAE). In each of these geographical units, the
study was implemented by a speciﬁc contract research
organisation (CRO). The number of subjects recruited by
country is illustrated in Fig. 1.
Feasibility study
Prior to initiating the main survey, a feasibility pilot study
was performed in all target countries except Pakistan in
order to investigate the performance of the telephone
random-dialling method for recruiting subjects and to assess
the acceptability of the questionnaires.
Recruitment of the study population
The study was carried out by telephone, allowing the
systematic screening of a national sample in order to
identify a national probability sample of individuals likely
to have COPD. A sample of at least 10,000 subjects among
the adult general population of each country or zone
was generated using a random stratiﬁed sampling method.
Telephone numbers (landline and mobile phones) were
randomly generated using an assisted random-digit dialling
procedure. Numbers were generated by bloc. In a ﬁrst step,
a bloc of 5,000 random phone numbers (landline and mobile)
was generated by country or zone and these numbers were
all called in order to evaluate the proportion of exploitable
numbers. On this basis, the number of further blocs of
numbers to be generated in order to achieve the target of at
least 10,000 subjects could be estimated. Successive blocs
of numbers were then selected until the pre-speciﬁed quota
of 10,000 interviews was completed in each participating
country or zone. In order to optimise the response rates, the
next bloc of numbers was only released when the previous
bloc had been completed. The process continued until a
target sample of at least 10,000 subjects had agreed to
participate in each deﬁned country or zone (Table 1).
Subjects were contacted by dialling each telephone
number on the list consecutively. In order to optimise
contact, each number was dialled up to 15 times on different
days including weekends and at different times including
evenings until contact was established. After 15 attempts
the outcomes were categorised as interview, formal refusal
or not a valid number (out of service, professional number
or fax or not reachable). When telephone contact was
established, the interviewer assessed the eligibility of
Table 1
Number of subjects in each target sample
Country or zone Target sample
Egypt 10,000
Pakistan 10,000
Saudi Arabia 10,000
Turkey 10,000
Middle East zone
Jordan 3,500
Lebanon 3,500
Syria 3,500
UAE 3,500
North Africa zone
Algeria 4,000
Morocco 4,000
Tunisia 2,000
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Generated numbers
N = 457,258
Contacts
N = 210,121
Eligible numbers
N = 165,274
Eligible subjects
N = 65,154
Screening quesonnaire
N = 62,086
Una ributed number
or fax
N = 180,192
Non eligible number
N = 31,304
Non eligible subject
N = 95,157
Refusal
N = 3,068
No reply aer 15 calls
N = 50,460
Refusal before number
eligibility assessed
N = 13,543
Refusal before subject
eligibility assessed
N = 4,750
Figure 2. Details of the recruitment phase. Open boxes: subjects taken into account in the determination of the response rate.
the telephone number. Work telephone numbers were
considered to be non-eligible. For eligible landline or
mobile telephone numbers, the interviewer characterised
the subjects in terms of age, gender and region.
Inclusion and exclusion criteria
During the screening phase, male or female subjects aged
40 years, who agreed to participate in the study were
enrolled. Subjects not domiciled in the country or those of
foreign origin resident in the country for less than six months
at the time of the interview or having comorbid mental
illness were excluded. Eligible subjects were provided with
standardised information about the study, not mentioning
COPD in order to avoid potential bias, and were invited to
respond to the screening questionnaire.
Subjects recruited
The total number of subjects involved in the recruitment
phase for all participating countries is summarised in Fig. 2
and for each country separately in Table 2.
A total of 457,258 telephone numbers was generated and
contact was established with a total of 210,121 subjects,
of whom 65,154 were eligible to participate in the study.
Finally, 62,086 eligible subjects accepted to participate
in the study and constituted the screening population.
The overall response rate, deﬁned as the ratio between
the number of subjects who completed the screening
questionnaire and the number of potentially eligible
subjects, was 74.2%, ranging from 37.3% in Pakistan to
95.5% in Algeria. As well as subjects who refused to
participate, the potentially eligible subjects also included
the sets of numbers whose eligibility could not be assessed
and the individual subjects whose eligibility could not be
assessed. Since these groups of undetermined eligibility will
include an undeﬁned number of non-eligible subjects, the
response rate provided should be considered a conservative
estimate.
In order to ensure representativeness of the population of
each country as a whole, cross-stratiﬁcation was performed
to ensure representativeness by age and gender, and
margin stratiﬁcation to ensure representativeness by region
(Table 3).
Data collection
Telephone interviews were conducted by ten to twenty
interviewers per country. Each interviewer was trained
about the study protocol and COPD. Each interview lasted
around ﬁve minutes for the screening questionnaire and
around forty-ﬁve minutes for the detailed questionnaire.
In a ﬁrst step, the interviewer administered a screening
questionnaire using the Computer Assisted Personal Inter-
viewing (CAPI) method or equivalent. No gifts or incentives
were offered to participating subjects.
Subjects fulﬁlling the screening criteria (see below)
were invited to complete a more detailed questionnaire
on the disease (detailed COPD patient questionnaire), as
well as two questionnaires assessing the severity of COPD
(CAT questionnaire) and cost of disease (cost of disease
questionnaire). A subset of subjects was asked to perform
spirometry in selected centres or at home. All these
questionnaires are detailed below. The screening and the
detailed COPD patient questionnaires used in this study have
been developed from the validated questionnaires provided
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in the Confronting COPD study which was carried out in
North America and Europe.26 A method of translation, back-
translation, medical review and linguistic validation was
used in order to ensure trans-cultural validation of the
questionnaires. All questionnaires were initially translated
from English to classical Arabic, Turkish, French and Urdu
by local experts. In North Africa, where some groups of
the population could potentially not understand some items
or words in classical Arabic or French, the questionnaires
were translated into local dialectal Arabic or into Berber
languages by the local expert.
Screening questionnaire
The screening questionnaire consisted of eighteen questions
relating to patient demographics, smoking habits and
respiratory symptoms (Table 4).
The objective was to identify eligible subjects who
fulﬁlled the epidemiological case deﬁnition of COPD (see
Box 1).
The screening questionnaire included six questions to
collect data on the presence of respiratory symptoms
that fulﬁlled the deﬁnition of chronic bronchitis or
breathlessness (symptom criterion), one question to conﬁrm
whether COPD or chronic bronchitis or emphysema had been
diagnosed (diagnosis criterion), and six questions to collect
information on daily smoking, type of tobacco used and
frequency of consumption (smoking criterion).
Four categories of subject populations were deﬁned
(see Box 1). The ﬁrst category concerns eligible subjects
fulﬁlling the smoking criterion as well as either the symptom
criterion or the diagnosis criterion. This population was
identiﬁed as the “COPD” population. The second category,
identiﬁed as the “Possible COPD” population, corresponds
to subjects fulﬁlling either the smoking criterion or the
symptoms criterion or the diagnosis criterion. The third
category, corresponding to subjects not fulﬁlling any of
these criteria, was identiﬁed as the “Non-COPD” population.
The fourth category, identiﬁed as the “Potential COPD”
population, corresponds to those fulﬁlling at least one of
these criteria and thus includes all the “COPD” population
as well as subjects in the “Possible COPD” population
fulﬁlling only a single criterion. The purpose of the “Possible
COPD” category was just to constitute the “Potential COPD”
category, and data for this group have not been analysed
speciﬁcally.
The data collected in this questionnaire concerned a
total of 62,086 subjects in all participating countries. These
subjects are also described elsewhere in this supplement in
articles dedicated to smoking habits27 and distribution of
COPD symptoms.28
Detailed COPD patient questionnaire
Subjects included in the “COPD” population were considered
as positively screened and invited to undergo a more
detailed telephone questionnaire on the disease (detailed
COPD patient questionnaire). This questionnaire consists
of seventy-seven questions collecting information on risk
factors, disease history, clinical symptoms, impact on daily
life and disease management. A total of 2,187 “COPD”
subjects were enrolled and 1,392 of them completed the
detailed COPD questionnaire (Table 5).
The data collected are presented in the articles dedicated
to disease management,29 to burden of disease,30 to
attitudes and beliefs towards COPD31 and to healthcare
resource consumption.32
Cost of disease questionnaire
All subjects in the “COPD population” were invited to
complete a cost of disease questionnaire. This questionnaire
aimed to assess the cost of COPD and its impact on quality
of life and health. It was completed by 1,038 subjects,
corresponding to around half (47.6%) of the “COPD”
population.
Spirometry
An ancillary study collected data on respiratory function
using spirometry from a subpopulation of subjects in order to
assess severity of the disease and potentially to substantiate
the diagnosis using the GOLD deﬁnition (post-bronchodilator
FEV1/FVC ratio <0.7 AND FEV1 <80% predicted).
A randomly selected subgroup of subjects in the “Potential
COPD” group in each country was invited to undergo
spirometry. The target sample size was deﬁned for each
country according to local capacities in terms of health
care resources and the area of residence. The aim was to
recruit as many subjects as could be handled comfortably
with the resources available. Spirometry was performed
in speciﬁed centres or alternatively at home, if mobile
spirometry equipment (Vitalograph Alpha IV®) and trained
operators were available locally.
The target sample of the “Potential COPD” group was
contacted in order to propose participation and obtain
oral consent. For subjects who agreed to participate, an
appointment was made for the spirometric assessment.
When the subject attended the appointment, written
informed consent was obtained according to local laws
and subjects were assessed for comorbidities incompatible
with performing spirometry. Spirometry was performed
by a pulmonologist or experienced technician using a
standardised protocol and equipment that met or exceeded
the minimum performance standardised of the American
Thoracic Society.33 Lung function measurements were
obtained, FEV1 and FVC being assessed according to the
recommendations of the American Thoracic Society.33 At the
time of this visit, all subjects were also invited to complete
the COPD Assessment Test during a face-to-face interview
(see below) as well as a questionnaire on their air quality
environment.
Spirometry was proposed to 12,967 (67.2%) of the
“Potential COPD” group (Fig. 3). Of these, 5,213 (40.2%)
agreed to participate and 1,892 (14.6%) actually attended
their spirometry visit. Evaluable data were obtained from
1,847 subjects.
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COPD Assessment Test
A second ancillary study investigated health status using
the COPD Assessment Test (CAT).34,35 The CAT has been
translated into over ﬁfty different languages as part of a
large international programme available on the CAT website
(http://www.catestonline.org/). The Arabic and Turkish
versions used in this study were created and validated
as part of this programme. As well as collecting data on
the subjects included, this ancillary study also allowed
further psychometric validation of the CAT questionnaire
and determination of its internal consistency, reliability,
reproducibility, discriminant validity and sensitivity in a
previously unstudied population group. The CAT question-
naire was completed by three groups of subjects. The ﬁrst
group consisted of the ﬁrst 5,681 subjects, which represent
around 10% of the total number of screened subjects during
the BREATHE survey, and who were all invited to complete
the CAT at the end of the screening questionnaire. The
second group consisted of all subsequent subjects who
were identiﬁed as “COPD” (both smoking and symptoms/
diagnosis criteria fulﬁlled) during the screening phase, and
who completed the CAT at the same time as the detailed
COPD questionnaire and the cost of disease questionnaire
(Fig. 4). The third group consisted of all subjects who
attended a spirometry visit in the ancillary spirometry study
(see above), who completed the CAT during a face-to-face
interview at the time of the visit. Since the spirometry
study drew patients from the “Potential COPD” group, it was
possible for these subjects to have already completed the
CAT during the telephone interview, and two questionnaires
are thus available for these subjects.
A total of 8,368 complete questionnaires were collected
from 62,086 subjects, of which 5,639 derived from
screening of the initially enrolled subjects, from the
general population, 1,035 derived from the subsequently
enrolled “COPD” population and 1,694 from the subjects
assessed by spirometry. The latter group included 535
questionnaires from subjects in the “COPD” group and 174
in the “Possible COPD” group who had previously completed
a questionnaire during the screening phase. Further details
of the methodology as well as the results of the CAT study
are described elsewhere in this supplement.36
Statistical analysis
Data are presented as proportions and means with standard
deviations (SD), or medians with interquartile ranges (IQR).
95% conﬁdence intervals (95%CI) were calculated for
binomial data. Associations between categorical variables
were estimated using the c2 test and the Mantel Haenszel
test for trends, as appropriate. Two-sided tests were
used in all cases and a probability threshold of 0.05 was
considered signiﬁcant. Bonferroni correction was applied
for multiple testing procedures, when appropriate. All
statistical analyses were performed using SPSS Version 17
(IBM Corp, Armonk, NY).
Prevalence rates were estimated separately for each
country by dividing the total number of positively screened
subjects by the total number of screened subjects.
Prevalence rates were adjusted for age and gender. The
response rate was the overall number of screened subjects
divided by the total number of potentially eligible subjects
for whom contact could be established. More speciﬁc
statistical approaches are described wherever appropriate
in the other articles in this supplement.
Discussion
In this survey, over 60,000 subjects in eleven countries in the
MENA region were screened for information on respiratory
symptoms and smoking habits. The response rate was 70%
in all countries (except Pakistan, where the conduct of the
study was affected by geopolitical instability), suggesting
that the data obtained should be relatively representative
of the target populations in each country. Comparison of
the demographic features of the screened subjects with
national census data suggests that the survey population
was indeed representative. It should be noted that the study
was performed during a year (2011) of considerable political
movement in several of the participating countries (Arab
spring).
When planning the BREATHE study, a number of strategic
decisions had to be taken. The ﬁrst related to the reference
frame. Previous large regional epidemiological studies on
COPD have used either home-based interviews exclusively,
such as Confronting COPD,26 or systematic standardised
spirometry, such as BOLD12 or PLATINO.25 The spirometry-
based surveys have the advantage of providing reliable data
on the number of COPD cases, since these are ascertained
objectively by spirometry, but may suffer from suboptimal
representativity as the evaluated subjects have to be
able and willing to go to a health centre for spirometry
evaluation. On the other hand, the interview-based surveys
rely on respondent self-reporting for identifying COPD
cases, which may be less accurate, but can provide more
complete coverage of the population. In the BREATHE
survey, our ambitious goal was to combine the advantages
of both reference frames in a clustered design in which
spirometry was proposed to a subgroup of respondents
who reported features consistent with an epidemiological
deﬁnition of COPD. In this way we hoped to optimise the
estimate of the prevalence of COPD by combining the
high-quality numerator of the spirometry studies with the
high quality denominator of the interview-based study. This
goal was only partially met. Although the response rate
to the interviews of 70% was respectable, the proportion
of subjects undergoing spirometry was low (14.2% of
respondents to whom it was proposed). Our study illustrates
the difﬁculty of collecting information necessitating speciﬁc
paraclinical tests using random sampling of the general
population. Approaches such as that used in the BOLD
studies,12 where specialist centres targeted individuals
living in their catchment area, may be better adapted to
collecting such data.
The second major strategic choice that had to be made
related to data acquisition. We chose to contact respondents
through random telephone dialling. Face-to-face interviews
during household visits were not practical for the screening
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Table 4
Questions presented in the screening questionnaire
1. (What is the gender/sex of the respondent)?
a. Male
b. Female
2. Where do you fall in the following age range?
a. <25 years
b. 26 39 years
c. 40 49 years
d. 50 59 years
e. 60 years
3. How many phone numbers do you have other than this one (mobile and landline)?
4. Do you suffer from any of the following health conditions?
a. Diabetes
b. Hypertension
c. Any cardio-vascular diseases
d. Renal disease
e. Neurological disease
f. Liver disease
g. Asthma
h. Migraine
i. Eye diseases
j. Digestive diseases
k. Any other condition
If yes, specify
5. Do you suffer from persistent bronchitis or coughing with phlegm or sputum from the chest for the last 2 years or more?
6. How many MONTHS in the past 12 months have you had bronchitis or chronic coughing with phlegm/sputum from the chest?
7. For how many years have you had bronchitis or chronic coughing with phlegm/sputum from the chest for at least 3 months?
8. At what age did you ﬁrst develop bronchitis or coughing with phlegm or sputum?
9. Have you been repeatedly short of breath over the past 12 months?
10. At what age did you ﬁrst develop shortness of breath?
11. Do you suffer from any of the following respiratory conditions?
a. Emphysema
b. Chronic bronchitis
c. Chronic Obstructive Pulmonary Disease (COPD)
or Chronic obstructive airways disease (COAD)
or Chronic obstructive lung disease (COLD)
d. a1 antitrypsin deﬁciency
12. At what age did you ﬁrst develop this respiratory condition?
13. Have you ever smoked cigarettes on a daily basis?
14. If yes in Q13, for how many years, in total, have you smoked cigarettes on a daily basis?
15. If yes in Q13, how many cigarettes do you/did you smoke per day, on average?
16. Have you ever smoked waterpipes on a daily basis?
17. If yes in Q16, for how many years, in total, have you smoked waterpipes on a daily basis?
18. If yes in Q16, how many hours do you/did you smoke waterpipes per day, on average?
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Box 1. Deﬁnitions used in the study
Deﬁnition of chronic bronchitis: The GOLD deﬁnition of chronic bronchitis was used in the study: “the presence of
cough and sputum production for at least 3 months in each of two consecutive years”, not necessarily associated with
airﬂow limitation.1
Epidemiological deﬁnition of COPD: “COPD” cases were deﬁned as eligible subjects fulﬁlling BOTH the following
criteria 1 and 2:
(1) EITHER
(a) Diagnosis criterion: already diagnosed with COPD, emphysema or chronic bronchitis, OR
(b) Symptom criterion: presenting EITHER with symptoms that fulﬁl the deﬁnition of chronic bronchitis OR with
dyspnoea.
(2) AND
Smoking criterion: lifetime smoking exposure of 10 pack·years.
Study populations: Four populations were characterised:
“COPD” population: eligible subjects fulﬁlling the epidemiological deﬁnition of COPD (both smoking and
symptoms/diagnosis criteria fulﬁlled)
“Possible COPD” population: eligible subjects fulﬁlling either the smoking criterion or the symptoms/diagnosis
criterion, but not both.
“Non-COPD” population: eligible subjects fulﬁlling neither criterion.
“Potential COPD” population: eligible subjects fulﬁlling at least one criterion. This group thus includes both the “COPD”
and the “Possible COPD” groups.
Table 5
Classiﬁcation of eligible subjects according to COPD criteria and number of detailed COPD interviews
Gender, n (%)
Men Women
Age groups, n (%)
40 49 years 50 59 years 60 years
Total, n (%)
Subjects screened 31,673 (51.0%) 30,413 (49.0%) 28,815 (46.4%) 18,427 (29.7%) 14,844 (23.9%) 62,086 (100%)
Smoking and symptoms/diagnosis criteria fulﬁlled (“COPD” population)
Yes 1,632 (5.2%) 555 (1.8%) 895 (3.1%) 726 (3.9%) 566 (3.8%) 2,187 (3.5%)
No 29,938 (94.5%) 29,769 (97.9%) 27,829 (96.6%) 17,656 (95.8%) 14,222 (95.8%) 59,707 (96.2%)
Possible COPD 11,254 (35.5%) 5,847 (19.2%) 7,306 (25.4%) 5,369 (29.1%) 4,426 (29.8%) 17,101 (27.5%)
No COPD 18,684 (59.0%) 23,922 (78.7%) 20,523 (71.2%) 12,287 (66.7%) 9,796 (66.0%) 42,606 (68.6%)
Missing data 103 (0.3%) 89 (0.3%) 91 (0.3%) 45 (0.2%) 56 (0.4%) 192 (0.3%)
COPD interviews
Yes 1,052 (64.5%) 340 (61.3%) 535 (59.8%) 487 (67.1%) 370 (65.4%) 1,392 (63.8%)
No 580 (35.5%) 215 (38.7%) 360 (40.2%) 239 (32.9%) 196 (34.6%) 795 (36.4%)
phase due to the large areas with poor access to be
covered in certain countries. Although this would probably
have facilitated contact with respondents and potentially
improved response rates, making household visits would
have entailed many months of ﬁeldwork in order to reach
the target sample size set for the survey. A postal survey
was rejected given the low response rate often associated
with this form of data acquisition, and because literacy rates
were low in some of the regions targeted. Nonetheless,
it is recognised that anonymous data collection through
a postal survey may generate more accurate data with
regard to culturally sensitive items such as smoking habits
than direct interview. Random telephone dialling was thus
chosen for the screening phase of the study as it provides
the best compromise to reach a representative sample of
the target population with an acceptable response rate
in a relatively short timeframe. It was recognised that
contacting respondents by telephone may limit enrolment
of women, who may not participate in telephone interviews
because of cultural or religious barriers, and for this reason,
enrolment was stratiﬁed by gender. In the event, the
expected cohort of women was enrolled in all countries
except Saudi Arabia and Pakistan, where women were
somewhat under-represented.
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Potenal COPD
N = 19,288
Proposed spirometry
N = 12,967
Agreed to parcipate
N = 5,213 (40.2%)
Exploitable spirometry test
N = 1,847
Response rate = 14.2%
Absent for the test
N = 3,366 (25.9%)
Refusal
N = 7,754 (59.8%)
Performed spirometry
N = 1,892 (14.6%)
Figure 3. Study populations for the ancillary spirometry study.
Eligible subjects
N = 58,431
Arabic-speaking
N = 43,345
‘COPD CAT populaon’ N = 1,035
Met COPDcriteria
N = 205
Not COPD
N = 5,434
COPDcriteria met
+ proposed CAT
N = 1,901
COPDcriteria unmet
N = 50,849Completed CAT
‘ ’General CAT populaon
N = 5,639
Not proposed CAT
N = 52,750
Completed CAT
N = 830
Performed CAT
N = 833
Proposed CAT
N = 5,681
Screening populaon
N = 62,086
Turkish-speaking
N = 15,086
Urdu-speaking
N = 3,655
Randomisaon
Performed CAT
N = 5,681
Figure 4. Study populations for the CAT study.
It was decided to exploit both mobile telephone numbers
and landlines. In many countries in the region, landline
coverage is poor, for example in Algeria where only 43.1%
of households have access to a landline, compared to 92.7%
of the population who have a mobile telephone.37 Use
of landlines only would thus have introduced a potential
sampling bias due to the unequal distribution of landline
coverage, for example leading to an over-representation of
urban areas. The extent of landline and mobile telephone
coverage in each participating country is provided in Table 6.
On the other hand, respondents reached through a landline
at home may be more receptive to being interviewed
than those contacted outside on their mobile telephone.
Indeed, during the feasibility study, the acceptance rate for
S14 A. El Hasnaoui et al.
mobile telephone contacts in Turkey was poor. Since landline
coverage is extensive in this country (81.6%), it was decided
to exploit landlines only in Turkey.
Table 6
Landline and mobile telephone coverage in the general
population of participating countries a
Country Total population Subscribers
(% of general population)
Landline Mobile
Algeria 34,080,030 43.1% 92.7%
Egypt 72,798,031 54.6% 87.0%
Jordan 5,103,639 47.7% 91.0%
Lebanon 3,759,135 71.9% 83.0%
Morocco 29,891,708 65.9% 87.8%
Pakistan 132,352,279 96.0% 86.0%
Saudi Arabia 22,678,262 56.2% 89.8%
Syria 17,874,589 96.4% 70.0%
Tunisia 9,910,872 54.7% 87.4%
Turkey 73,722,988 81.6% 79.5%
UAE 4,106,427 100.0% 78.0%
a Data were obtained from the relevant government sources
in each country.
Interviewees were thus reached by both mobile tele-
phones and landlines, proportionally to the telephone
coverage in each country, with the exception of Turkey,
where only landlines were used. The number of successive
blocs of numbers released was adapted to each country
according to telephone coverage and use patterns. In
order to optimise representativeness, each successive bloc
was only released when the previous one had been
completed, either through a successful contact or through
failure to establish contact after ﬁfteen attempts. In
each call centre, the most successful interviewers were
systematically assigned to numbers that appeared difﬁcult
to contact or where respondents who had been asked to be
called back were difﬁcult to recontact.
This method proved to be successful and nearly 500,000
numbers were generated and dialled over a period of
56 weeks, resulting in over 200,000 contacts and the
identiﬁcation of 65,154 potentially eligible subjects. Less
than ﬁve percent of these potentially eligible subjects
contacted refused to participate. The large number of
individuals screened allowed the constitution of a panel
of 2,187 subjects fulﬁlling the epidemiological deﬁnition
of “COPD” who reported both symptoms consistent with
a diagnosis of COPD and regular smoking. It has been
possible to collect a large amount of data from this panel
through the in-depth survey questionnaires, and the panel
thus constitutes, to our knowledge, the largest database
of potential COPD patients identiﬁed from the general
population in this region of the world.
The study methodology has a number of limitations, most
of which are direct consequences of the sampling and
data collection methods which were chosen to optimise
the reach of the survey. For example, contacting potential
participants by telephone necessarily excludes individuals
who do not have telephones, who may be older or live in
more remote rural areas. This may introduce some bias if,
for example, these individuals present different risk factors.
A related issue is that the criteria for the epidemiological
deﬁnition of COPD required respondents to be smokers. This
requirement, which was also used in the Confronting COPD
surveys,26 was motivated by the fact that smoking is by far
the most important risk factor for COPD in industrialised
countries. However, other risk factors, such as exposure
to smoke from biomass fuel, may be very important in
some regions of the MENA region. For this reason, the
epidemiological deﬁnition used may underestimate the real
prevalence of COPD symptoms. Finally, data were collected
over the telephone by lay interviewers with no attempt
to ascertain information on clinical symptoms, diagnosis or
treatments used, which may have compromised accuracy.
Similarly, since data were collected by direct interview
rather than on an anonymous postal questionnaire, it is
possible that the accuracy of some of the data, notably with
respect to smoking habits, may be suboptimal.
In conclusion, the BREATHE study has collected a large
amount of information on COPD related variables from an
extensive cohort of members of the general population
of countries in the MENA region using a standardised
methodology comparable to that previously used in the
Confronting COPD surveys in North America and Europe.
The data collected allow the frequency of smoking and
of respiratory symptoms in participating countries to be
estimated and compared with precision. The detailed
ﬁndings of the BREATHE study are described in other articles
in this supplement.
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